Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With a PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer

NCT03308942 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT03308942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03308942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With a PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer
Lead sponsor
Tesaro, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 29, 2017
Completion date
August 31, 2021
Enrollment
53 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms